КЛИНИЧЕСКАЯ ЭФФЕКТИВНОСТЬ КОМБИНИРОВАННОГО ПРЕПАРАТА L- АРГИНИНА И ЛЕВОКАРНИТИНА У БОЛЬНЫХ ПОЖИЛОГО ВОЗРАСТА С ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА И САХАРНЫМ ДИАБЕТОМ
Ключевые слова:
сердечно-сосудистые заболевания, артериальная гипертензия, ишемическая болезнь сердца, хроническая сердечная недостаточность, метаболическая терапия, Л-аргинин, левокарнитинАннотация
С точки зрения патофизиологии сердечно-сосудистых заболеваний метаболическая коррекция явлется аргументированным подходом. Тот постулат, который в настоящее время утверждает, что сокращающееся сердце остро нуждается в энергетическом топливе, в настоящее время не вызывает сомнений. Под метаболической терапией (МТ) кардиологии понимают улучшение энергетического метаболизма в сердечной мышце путем фармакологического управления процессами образования и переноса энергии на уровне кардиомиоцитов без влияния на коронарный кровоток и системную гемодинамику. Принципиально можно выделить два основных направления МТ – оптимизацию процессов образования и расхода энергии, а также нормализацию баланса между интенсивностью свободнорадикального окисления и антиоксидантной защитой.
Библиографические ссылки
Ageev F.T. Correction of endothelial function is the key to the success of treatment of cardiovascular diseases / F.T. Ageev // Heart. Journal for practicing physicians -2003.-№1- P.22-26.
Arginine in medical practice / Yu. Stepanov, I.N.Kononov, A.I.Zhurbina, A.Y.Filippova // Journal of the Academy of Medical Sciences of Ukraine - 2004.-№10(1) - P.340-352
Babushkina A.V. L-arginine from the point of view of evidence-based medicine // Ukrainian Medical Journal - 2009.-№6 (74) - p. 1-5./www.umj.com.ua/
The value of L-arginine in the treatment of patients with cardiovascular pathology / M.I. Lutai, V.V. Bugayenko, O.I. Moiseenko, L.O. Mushtenko, V.A. Slobodsky // Ukrainian Cardiology Journal - 2011.- №4.- P.98-110.
Cardiology: national guide / edited by E.V. Shlyakhto - 2nd ed.
Konopleva L.F. L-arginine in coronary heart disease: research continues / L.F. Konopleva, E.V. Andreev // Therapy. - 2010.- №10(51).- pp.64-68
The role of endothelial dysfunction in the genesis of cardiovascular diseases / V.N. Elsky, N.T. Vatutin, N.V. Kalinkina, A.M. Salakhova // Journal of the Academy of Medical Sciences of Ukraine. 2008 - №14(1) - P.51-62.
Slobodskyi V.A. Advantages of combined infusion and oral form of L-arginine in treating patients with stable angina pectoris // Zdorovye Ukrainy. - 2010. - №2-3. - P.17-20. Sizova Zh.M., Shikh E.V., Makhova A.A. Application of L-carnitine in general medical practice. Therapeutic archive. 2019; 91 (1): 114-20.
Efficacy of the drug tivortin in the treatment of patients with stable angina pectoris / Lutai YA, Kryuchkova ON, Itskova EA, Lebed EI // Crimean therapeutic journal.2013.-№1(20).-P.63-69
Boger R.H. The pharmacodynamics of L-arginine // J. Nutr. - 2007.- №137 (6 Suppl.2) -p.1650- 1655.
Davignon J. Role of endothelial dysfunction in atherosclerosis / J. Davignon, P. Ganz//Circulation. - 2004. - Vol.109. - P.27-32.
Division of Cardiovascular Diseases and Internal Medicine. Mayo Clinic College of Medicine, Rochester, Minn 55905, USA. Current and future treatment strategies for refractory angina // Mayo Clin. Proc.-2004.-Vol.79(10). -P.1284-1292
Efficacy and safety of oral L-arginine in acute myocardial infarction. Results of the multicenter, randomized, double-blind, placebo-controlled ARAMI pilot trial/B.Bednarz, T.Jaxa-Chamiec, P.Maciejewski et al.// Kardiol. Pol. -2005.-Vol.62(5)-P.421-427.
Lubos E. Role of oxidative stress and nitric oxide in atherothrombosis/E.Lubos, D.E.Handy, J.Loscalzo//Front. Biosci.-2009.- Vol.13.-P.5323-5344.
2013 ESC guidelines on the management of stable coronary artery disease. The Task Force on managing stable coronary artery disease of the European Society of Cardiology // Eur.Heart J. - 2013. - Vol.34. - p.2949-3003
Marunych RY, Gornytska OV, Gudzenko AV et al. (2021). The role of endothelium in regulating blood aggregation in normal atherosclerosis and hypertension. Physiol. journal, Vol. 67, No. 3.
Canto J. G., Kiefe C. I., Rogers W. J. et al. (2011). Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction. JAMA. Nov 16; 306(19): 2120-7. doi: 10.1001/jama.2011.1654.
Nilsson P. M. Early vascular aging (EVA): consequences and prevention. Vasc Health Risk Manag.; 4: 547-52. doi: doi.org/10.2147/VHRM.S1094.
Schmitt M., Avolio A., Qasem A. et al. (2005). Basal NO locally modulates human iliac arterial function in vivo. Hypertension. Jul; 46(1): 227-31. doi: 10.1161/01.HYP.0000164581.39811.bd.
Schillaci G, Verdecchia P, Porcellati C, et al. (2000). Continuous relationship between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension. Feb; 35(2): 580-6. doi: 10.1161/01.hyp.35.2.580.
Tomiyama H, Ishizu T, Kohro T, et al. (2018). Longitudinal association among endothelial function, arterial stiffness and subclinical organ damage in hypertension. Int J Cardiol. Feb 15; 253: 161-166. doi: 10.1016/j.ijcard.2017.11.022.
Perticone F., Ceravolo R., Candigliota M. et al. (2001). Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C. Diabetes. Jan; 50(1): 159-65. doi: 10.2337/diabetes.50.1.159.
Sokolova LK, Pushkarev VM, Tronko MD (2019). L-arginine in normal and pathology. Endocrinology. Vol. 24. no. 4. 373-385. doi: 10.31793/1680-1466.2019.24-4.373.
Weckman A. M., McDonald C.R., Baxter J.B. et al. (2019). Perspective: L-arginine and L- citrulline Supplementation in Pregnancy: A Potential Strategy to Improve Birth Outcomes in Low-Resource Settings. Adv Nutr. Sep 1; 10(5): 765-777. doi: 10.1093/advances/nmz015.
Mishchenko LA (2020). Organ-protective capabilities of L-arginine in the treatment of patients with arterial hypertension. "Health of Ukraine of the 21st Century" № 23 (492).
Sepandi M., Abbaszadeh S., Qobady S. et al. (2019). Effect of L-Arginine supplementation on lipid profiles and inflammatory markers: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. Oct; 148: 104407. doi: 10.1016/j.phrs.2019.104407.
Yin W. H., Chen J. W., Tsai C. et al. (2005). L-arginine improves endothelial function and reduces LDL oxidation in stable coronary artery disease patients. Clin Nutr. Dec; 24 (6): 988-97. doi: 10.1016/j.clnu.2005.07.003.
Kutovoy A. B., Lyulko I. V., Amro A. et al. (2014). L-Arginine in complex therapy of chronic ischemia of lower limbs in atherosclerosis. Serce i sudini, No. 3, P. 89-92.
Lekakis J. P., Papathanassiou S., Papaioannou T. G. et al. (2002). Oral L-arginine improves endothelial dysfunction in patients with essential hypertension. Int J Cardiol. Dec; 86 (2-3): 317-23. doi: 10.1016/s0167-5273(02)00413-8.
West S. G., Likos-Krick A., Brown P. et al. (2005). Oral L-arginine improves hemodynamic responses to stress and reduces plasma homocysteine in hypercholesterolemic men. J Nutr. Feb; 135 (2): 212-7. doi: 10.1093/jn/135.2.212.
Bahadoran Z., Mirmiran P., Tahmasebinejad Z. et al. (2016). Dietary L-arginine intake and the incidence of coronary heart disease: Tehran lipid and glucose study. Nutr Metab (Lond). Mar 15; 13: 23. doi: 10.1186/s12986-016-0084-z.
Xu Y., Jiang W., Chen G. et al. L-carnitine treatment of insulin resistance: A systematic review and meta-analysis //Adv. Clin. Exp. Med. – 2017. – Vol. 26 (2). – P. 333–338.doi: 10.17219/acem/61609.
